At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 110 enrolled
Drug / intervention
Dexamethasonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19
In Brief
A Phase 4 clinical trial evaluating Dexamethasone for Covid19. Completed, enrolled 110 participants across 1 site.
Detailed Summary
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJan 2021
Primary CompletionDec 2021
Study CompletionMar 2022
TodayJul 2026
First PostedJan 13, 2021
Enrollment StartJan 21, 2021
Primary CompletionDec 31, 2021
Study CompletionMar 4, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.5 years ago
Interventions
Dexamethasonedrug
Dexamethasone